{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:56Z","timestamp":1786980896796,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01506-x","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T10:11:34Z","timestamp":1738231894000},"page":"181-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage"],"prefix":"10.1007","volume":"43","author":[{"given":"Lixia","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"1506_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1506_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11912-021-01099-7","volume":"23","author":"A Chambers","year":"2021","unstructured":"Chambers A, Kundranda M, Rao S, Mahmoud F, Niu J (2021) Anti-angiogenesis revisited: combination with immunotherapy in solid tumors. Curr Oncol Rep 23:100. https:\/\/doi.org\/10.1007\/s11912-021-01099-7","journal-title":"Curr Oncol Rep"},{"key":"1506_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet"},{"key":"1506_CR4","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1158\/1078-0432.CCR-21-3807","volume":"28","author":"G Verset","year":"2022","unstructured":"Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A et al (2022) Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial. Clin Cancer Res 28:2547\u20132554. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3807","journal-title":"Clin Cancer Res"},{"key":"1506_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J et al (2020) Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 21:571\u2013580. https:\/\/doi.org\/10.1016\/S1470-2045(20)30011-5","journal-title":"Lancet Oncol"},{"key":"1506_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"1506_CR7","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.3748\/wjg.v29.i15.2261","volume":"29","author":"A Bhatt","year":"2023","unstructured":"Bhatt A, Wu J (2023) Immunotherapy for recurrent hepatocellular carcinoma. World J Gastroenterol 29:2261\u20132271. https:\/\/doi.org\/10.3748\/wjg.v29.i15.2261","journal-title":"World J Gastroenterol"},{"key":"1506_CR8","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1186\/s12885-021-08859-5","volume":"21","author":"L Xue","year":"2021","unstructured":"Xue L, Gao X, Zhang H, Tang J, Wang Q, Li F et al (2021) Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment. BMC Cancer 21:1134. https:\/\/doi.org\/10.1186\/s12885-021-08859-5","journal-title":"BMC Cancer"},{"key":"1506_CR9","doi-asserted-by":"publisher","first-page":"101540","DOI":"10.1016\/j.esmoop.2023.101540","volume":"8","author":"C Mao","year":"2023","unstructured":"Mao C, Ji D, Ding Y, Zhang Y, Song W, Liu L et al (2023) Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia\/Ib open label, dose-escalation trials. ESMO Open 8:101540. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101540","journal-title":"ESMO Open"},{"key":"1506_CR10","doi-asserted-by":"publisher","first-page":"e1514","DOI":"10.1002\/onco.13817","volume":"26","author":"KP Papadopoulos","year":"2021","unstructured":"Papadopoulos KP, Harb W, Peer CJ, Hua Q, Xu S, Lu H et al (2021) First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors. Oncologist 26:e1514\u2013e1525. https:\/\/doi.org\/10.1002\/onco.13817","journal-title":"Oncologist"},{"key":"1506_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","volume":"14","author":"J Li","year":"2021","unstructured":"Li J, Deng Y, Zhang W, Zhou AP, Guo W, Yang J et al (2021) Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol 14:95. https:\/\/doi.org\/10.1186\/s13045-021-01095-1","journal-title":"J Hematol Oncol"},{"key":"1506_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY et al (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379:54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002","journal-title":"N Engl J Med"},{"key":"1506_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:282\u2013296. https:\/\/doi.org\/10.1016\/S1470-2045(18)30937-9","journal-title":"Lancet Oncol"},{"key":"1506_CR14","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/1078-0432.CCR-11-1991","volume":"18","author":"RS Finn","year":"2012","unstructured":"Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I et al (2012) Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2090\u20132098. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1991","journal-title":"Clin Cancer Res"},{"key":"1506_CR15","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389:2492\u20132502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2","journal-title":"Lancet"},{"key":"1506_CR16","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B et al (2020) Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol 6:e204564. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4564","journal-title":"JAMA Oncol"},{"key":"1506_CR17","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1200\/JCO.22.00972","volume":"41","author":"T Yau","year":"2023","unstructured":"Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A et al (2023) Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the CheckMate 040 trial. J Clin Oncol 41:1747\u20131757. https:\/\/doi.org\/10.1200\/JCO.22.00972","journal-title":"J Clin Oncol"},{"key":"1506_CR18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19:940\u2013952. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6","journal-title":"Lancet Oncol"},{"key":"1506_CR19","doi-asserted-by":"publisher","first-page":"e001945","DOI":"10.1136\/jitc-2020-001945","volume":"9","author":"JSL Wong","year":"2021","unstructured":"Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J et al (2021) Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer 9:e001945. https:\/\/doi.org\/10.1136\/jitc-2020-001945","journal-title":"J Immunother Cancer"},{"key":"1506_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J et al (2021) Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res 27:1003\u20131011. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2571","journal-title":"Clin Cancer Res"},{"key":"1506_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10585-014-9641-x","volume":"31","author":"JI Lee","year":"2014","unstructured":"Lee JI, Kim JK, Kim DY, Ahn SH, Park JY, Kim SU et al (2014) Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. Clin Exp Metastasis 31:475\u2013482. https:\/\/doi.org\/10.1007\/s10585-014-9641-x","journal-title":"Clin Exp Metastasis"},{"key":"1506_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","volume":"157","author":"F Kanwal","year":"2019","unstructured":"Kanwal F, Singal AG (2019) Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology 157:54\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2019.02.049","journal-title":"Gastroenterology"},{"key":"1506_CR23","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.21037\/jgo-23-590","volume":"14","author":"J Zhao","year":"2023","unstructured":"Zhao J, Guo Y, Feng T, Rong D, Kong X, Huang T et al (2023) Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol 14:2549\u20132558. https:\/\/doi.org\/10.21037\/jgo-23-590","journal-title":"J Gastrointest Oncol"},{"key":"1506_CR24","doi-asserted-by":"publisher","first-page":"909035","DOI":"10.3389\/fonc.2022.909035","volume":"12","author":"X Chen","year":"2022","unstructured":"Chen X, Li W, Wu X, Zhao F, Wang D, Wu H et al (2022) Safety and efficacy of sintilimab and anlotinib as first line treatment for advanced hepatocellular carcinoma (KEEP-G04): a single-arm phase 2 study. Front Oncol 12:909035. https:\/\/doi.org\/10.3389\/fonc.2022.909035","journal-title":"Front Oncol"},{"key":"1506_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N et al (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707\u2013716. https:\/\/doi.org\/10.1172\/JCI17423","journal-title":"J Clin Invest"},{"key":"1506_CR26","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","volume":"65","author":"BF Schrijvers","year":"2004","unstructured":"Schrijvers BF, Flyvbjerg A, De Vriese AS (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65:2003\u20132017. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00621.x","journal-title":"Kidney Int"},{"key":"1506_CR27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381\u20131389. https:\/\/doi.org\/10.1681\/ASN.2010020167","journal-title":"J Am Soc Nephrol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01506-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:40:40Z","timestamp":1746178840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01506-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01506-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This open-label, multicohort, and phase II clinical study consisted of two stages: a safety run-in stage and a dose expansion stage. The study has been registered on ClinicalTrials.gov (NCT05148195). The Institutional Review Boards of all participating hospitals approved the trial protocol, and all study participants provided written informed consent prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}